vernon-f-minton-v-jerry-w-gunn-individually-williams-squire-wren-llp ( 2009 )


Menu:
  •                           COURT OF APPEALS
    SECOND DISTRICT OF TEXAS
    FORT WORTH
    NO. 2-06-443-CV
    VERNON F. MINTON                                                       APPELLANT
    V.
    JERRY W. GUNN, INDIVIDUALLY;                                           APPELLEES
    WILLIAMS SQUIRE & WREN, LLP;
    JAMES E. WREN, INDIVIDUALLY;
    SLUSSER & FROST, L.L.P.;
    WILLIAM C. SLUSSER, INDIVIDUALLY;
    SLUSSER WILSON & PARTRIDGE LLP;
    AND MICHAEL E. WILSON, INDIVIDUALLY
    ------------
    FROM THE 48TH DISTRICT COURT OF TARRANT COUNTY
    ------------
    OPINION
    ------------
    This is a legal malpractice case in which the trial court rendered take-
    nothing summary judgment against appellant Vernon F. Minton in favor of
    appellees Jerry W. Gunn, individually, Williams Squire & Wren, LLP, James E.
    Wren, individually, Slusser & Frost, L.L.P., William C. Slusser, individually,
    Slusser Wilson & Partridge LLP, and Michael E. Wilson, individually, all of whom
    represented appellant in a prior patent infringement action. We affirm.
    I.   Brief Summary of Relevant Patent Law Rules
    A.    The On Sale Bar Rule
    This legal malpractice case involves application of a rule of federal patent law
    commonly referred to as the “on sale bar rule.” This rule provides that a patent is
    invalid if it was put into commercial use through a commercial offer for sale more
    than one year before the inventor applied for the patent. 1 Under federal patent law,
    the date one year prior to the patent application’s filing is commonly referred to as
    the “critical date.”2 A single commercial offer for sale before the critical date is
    generally sufficient to satisfy the on sale bar.3
    1
     Pfaff v. Wells Elecs., Inc., 
    525 U.S. 55
    , 67, 
    119 S. Ct. 304
    , 311–12
    (1998); Electromotive Div. of Gen. Motors Corp. v. Transp. Sys. Div. of Gen.
    Elec. Co., 
    417 F.3d 1203
    , 1209 (Fed. Cir. 2005). The on sale bar is statutorily
    grounded in 35 U.S.C. § 102(b), which states:
    A person shall be entitled to a patent unless—
    ....
    (b)   the invention was . . . on sale in this country, more than one
    year prior to the date of the application for patent in the United
    States . . . .
    35 U.S.C.A. § 102(b) (2001).
    2
     Baker Oil Tools, Inc. v. Geo Vann, Inc., 
    828 F.2d 1558
    , 1563 (Fed. Cir.
    1987).
    3
     See, e.g., 
    Pfaff, 525 U.S. at 67
    , 119 S. Ct. at 311; 
    Electromotive, 417 F.3d at 1209
    ; Paragon Podiatry Lab., Inc. v. KLM Labs., Inc., 
    984 F.2d 1182
    ,
    1188 (Fed. Cir. 1993) (per curiam).
    2
    B.    The Experimental Use Doctrine
    This case also involves the “experimental use doctrine.” This doctrine
    provides that if the purpose of an offer for sale is primarily experimental, as
    opposed to commercial, the patent is not invalidated under the on sale bar rule.4
    The ultimate question of whether a transaction is primarily for experimental
    use is one for the court to decide.5 When patent holders or inventors contend that
    the experimental use doctrine applies, they are arguing that the on sale bar does
    not apply because it has been negated by the primarily experimental purpose of the
    commercial offer for sale.6
    In determining whether the experimental use doctrine negates application of
    the on sale bar, the controlling issue is the purpose of the offer for sale, not the
    developmental status of the claimed invention.7 In other words, the question posed
    by the experimental use doctrine is not whether the invention is “under
    development, subject to testing, or otherwise still in its experimental stage” at the
    4
     See, e.g., 
    Electromotive, 417 F.3d at 1210
    .
    5
     See EZ Dock v. Schafer Sys., Inc., 
    276 F.3d 1347
    , 1351–52 (Fed. Cir.
    2002); see also Petrolite Corp. v. Baker Hughes Inc., 
    96 F.3d 1423
    , 1426 (Fed.
    Cir. 1996) (“Experimental use is a question of law to be analyzed based on the
    totality of the surrounding circumstances.”).
    6
     See, e.g., 
    Pfaff, 525 U.S. at 67
    , 119 S. Ct. at 311; 
    Electromotive, 417 F.3d at 1213
    .
    7
     Allen Eng’g Corp. v. Bartell Indus., Inc., 
    299 F.3d 1336
    , 1354 (Fed. Cir.
    2002); Scaltech Inc. v. Retec/Tetra, L.L.C., 
    178 F.3d 1378
    , 1384 n.1 (Fed. Cir.
    1999).
    3
    time of alleged sale, but whether the primary purpose of the inventor at the time of
    the sale was to conduct experimentation. 8         “Commercial exploitation, if not
    incidental to the primary purpose of experimentation, will result in an on sale bar,
    even if the invention was still in its experimental stage.”9
    II.   Factual and Procedural Background
    A.    The TEXCEN Lease
    In the early 1990s, appellant Vernon Minton, a former securities broker,
    formed a company called Texas International Stock Exchange, Inc. (TISE) and
    began developing a telecommunications network and software program called the
    Texas Computer Exchange Network (TEXCEN). TEXCEN was designed to allow
    individuals to trade securities through a computer network.
    In 1994, Minton approached R. M. Stark & Co. (Stark), a National Association
    of Securities Dealers, Inc. (NASD) brokerage/dealer, regarding a potential lease of
    the TEXCEN system. In January 1995, Minton sent Stark a letter stating that
    “[a]fter five years of development, TEXCEN is scheduled to be on-line during March
    or April of this year,” and that, “[a]s we discussed, [TISE] would appreciate your
    consideration in utilizing this program as an exclusive opportunity for enhanced
    order flow.” Minton attached a draft lease agreement that stated it was intended
    8
     Allen 
    Eng’g, 299 F.3d at 1354
    .
    9
     
    Scaltech, 178 F.3d at 1384
    n.1.
    4
    “for the purpose of opening brokerage accounts and executing trades for individuals
    using TEXCEN.”
    Throughout negotiations, Minton never told Stark that the TEXCEN lease
    would be for experimental purposes, although Stark was aware that the system
    needed to be reviewed and approved by NASD before he could use it. Stark and
    TISE entered the TEXCEN lease on March 8, 1995 (the TEXCEN Lease). The
    lease provided in part that (1) Stark had the right to open brokerage accounts and
    execute trades for its individual customers using TEXCEN, (2) TEXCEN would
    perform in a workmanlike manner, and (3) Stark would pay the lesser of $2,000.00
    or thirty percent of his gross revenues derived from TEXCEN per month for the term
    of the lease.
    B.    The ‘643 Patent
    On June 28, 1996, Minton filed his provisional application for United States
    Patent No. 6,014,643 (the ‘643 Patent), more than one year after signing the
    TEXCEN Lease. The ‘643 Patent was for an interactive securities trading system
    based substantially on TEXCEN. Indeed, Minton stated in his deposition that he
    provided a copy of the TEXCEN software assistance guide to his patent attorney,
    who used it to prepare the ‘643 Patent application. On January 11, 2000, the
    United States Patent and Trademark Office issued the ‘643 Patent.
    5
    C.    The Underlying Patent Litigation
    Minton filed suit against NASD in the United States District Court for the
    Eastern District of Texas to enforce the ‘643 Patent (the Patent Litigation), and later
    named NASDAQ Stock Market, Inc. (NASDAQ) as an additional defendant.
    Minton’s lawyers in the Patent Litigation, the appellees in this case, filed suit without
    knowledge of the TEXCEN Lease. Minton did not disclose the lease to appellees
    until after NASD and NASDAQ first revealed its existence in discovery conducted
    in the Patent Litigation.
    NASD and NASDAQ moved for summary judgment on Minton’s infringement
    claims on the ground that the ‘643 Patent was invalid under the on sale bar set forth
    in 35 U.S.C. § 102(b). They specifically contended that TEXCEN embodied
    Minton’s invention and that the lease, signed March 8, 1995, was a commercial
    offer for sale prior to the ‘643 Patent’s critical date of June 28, 1995. Appellees
    contend that, among other things, NASD and NASDAQ asserted that the TEXCEN
    Lease: (1) stated that TEXCEN was already developed; (2) offered TEXCEN for use
    with customers; (3) established payment terms; (4) warranted that TEXCEN would
    perform; and (5) stated that the lease was entered for the purpose of allowing
    individuals to open brokerage accounts and execute trades.
    Minton testified in the Patent Litigation that he expected to “benefit financially”
    from the lease and that, subject to regulatory approval, the lease allowed Stark to
    use TEXCEN “commercially.” Minton conceded that TEXCEN was offered for sale
    6
    more than one year before his patent was filed, but argued that TEXCEN did not
    include all of the elements of the ‘643 Patent’s claims and thus the on sale bar did
    not apply. The district court granted NASD and NASDAQ’s motion for summary
    judgment based upon the on sale bar.
    Following the district court’s order, Minton asked his attorneys to consider
    defense of the on sale bar on a new ground: that the purpose of the TEXCEN
    Lease was primarily experimental rather than commercial, and, therefore, the
    experimental use doctrine negated the on sale bar. A motion for reconsideration
    was filed on Minton’s behalf, with the experimental use issue briefed by new
    counsel. The district court considered Minton’s motion but declined to grant
    reconsideration.10
    Minton appealed, and the Federal Circuit affirmed the district court’s
    judgment.11      The Federal Circuit declined to address the merits of Minton’s
    argument based on the experimental use defense, stating that the district court was
    within its discretion in deciding not to consider experimental use as a defense and
    denying Minton’s motion for reconsideration, in part because the motion was based
    10
     See Minton v. Nat’l Ass’n of Sec. Dealers, Inc., 
    336 F.3d 1373
    , 1379
    (Fed. Cir. 2003) (noting that the district court likely denied Minton’s motion for
    reconsideration without considering the newly-raised experimental use defense
    because it denied Minton’s motion “tersely” and “for the reasons previously set
    forth in the court’s memorandum opinion”).
    11
     
    Id. at 1374,
    1381.
    7
    on an argument—the experimental use doctrine—that was not previously raised but
    “has long been a fixture of patent law.”12
    D.    The Legal Malpractice Action
    On August 25, 2004, Minton filed this legal malpractice action against
    appellees on the ground that they negligently failed to timely plead and brief the
    experimental use doctrine as a defense to NASD and NASDAQ’s showing that the
    section 102(b) on sale bar invalidated the ‘643 Patent.         Minton alleges that
    appellees’ negligence caused him to lose the Patent Litigation or, in the alternative,
    caused the Patent Litigation’s pretrial dismissal, depriving him of a settlement of
    $100,000,000.00.
    Appellees filed no-evidence and traditional motions for summary judgment
    attacking the causation element of Minton’s malpractice claim.13 Appellees argued
    that the experimental use exception did not apply to the TEXCEN Lease and, thus,
    as a matter of law, their alleged failure to timely plead and brief the defense could
    not have caused Minton harm in the Patent Litigation. The trial court ruled in
    12
     
    Id. at 1379.
          13
     See Tex. R. Civ. P. 166a(c), (i).
    8
    appellees’ favor and rendered a take-nothing judgment on all claims.14 This appeal
    followed.
    III.   Issues on Appeal
    Minton presents ten complaints challenging the trial court’s summary
    judgment:
    (1)   The trial court erred in ruling that the issue of whether the
    TEXCEN Lease was primarily for the purposes of experimental
    use was a question of law.
    (2)   The trial court erred as a matter of law by merely holding that
    the TEXCEN Lease had a commercial purpose rather than
    holding that the TEXCEN Lease’s purpose was “primarily”
    commercial.
    (3)   The trial court erred in concluding as a matter of law that the
    TEXCEN Lease had a commercial purpose.
    (4)   The trial court erred by improperly limiting the application of the
    experimental use exception to situations where the testing had
    to be on a required claim of the patent.
    (5)   The trial court erred in not considering testing of the invention
    that was not limited to the internet.
    14
     Appellees filed two joint motions, each seeking no-evidence and
    traditional summary judgments. The second joint motion was filed in response
    to Minton’s first amended original petition, which added a new damages
    theory—that Minton would have settled the Patent Litigation for at least
    $100,000,000.00 if his claims in that suit had not been dismissed on summary
    judgment under the on sale bar. Minton’s response to the second joint motion
    offered no new argument or evidence, but merely incorporated by reference his
    briefing and evidence filed in response to appellees’ first joint summary
    judgment motion. The trial court granted the relief sought in both joint motions.
    9
    (6)   The trial court erred as a matter of law by concluding that expert
    testimony was required to support the experimental use
    exception.
    (7)   The trial court erred by concluding that there was no evidence
    to support the experimental use exception.
    (8)   The trial court erred as a matter of law by concluding that any
    evidence tending to show the experimental use exception must
    be limited to the period up to and including June 28, 1996, the
    date of the ‘643 Patent application.
    (9)   The trial court abused its discretion in striking Minton’s exhibits
    32a, 32b, 39, and 40 as hearsay even though they met the
    hearsay exception for business records.
    (10) The trial court’s legal and evidentiary errors probably caused the
    rendition of an improper judgment and probably prevented
    Minton from properly presenting the case to this court.
    In a single cross-point, appellees complain of the trial court’s refusal to strike
    from the summary judgment record certain evidence submitted by Minton of alleged
    experimental use.
    Before addressing the merits of these complaints, we must decide whether
    we have subject matter jurisdiction over this case.
    10
    IV.   Subject Matter Jurisdiction
    Relying primarily on two decisions of the Federal Circuit, 15 and a decision of
    the Fifth Circuit that does not involve a legal malpractice claim, 16 Minton contends
    that we must dismiss this appeal for lack of subject matter jurisdiction because
    Minton’s legal malpractice claim “arises under” the exclusive patent law jurisdiction
    of the federal courts. We disagree and conclude that Minton’s claim does not
    confer exclusive subject matter jurisdiction on the federal courts.
    Under Texas law, “[w]hen a legal malpractice claim arises from earlier
    litigation, the plaintiff . . . bears the burden to prove he would have prevailed on the
    underlying cause of action.”17 In other words, the plaintiff must prove a case within
    a case.18 Thus, Minton’s ability to recover turns on whether he can prove by a
    preponderance of the evidence that the appellees’ allegedly negligent failure to
    15
     Air Measurement Techs., Inc. v. Akin Gump Strauss Hauer & Feld,
    L.L.P., 
    504 F.3d 1262
    (Fed. Cir. 2007) (holding that state law claim for legal
    malpractice involving prior patent law litigation “arises under” federal law);
    Immunocept, LLC v. Fulbright & Jaworski, LLP, 
    504 F.3d 1281
    (Fed. Cir. 2007)
    (same).
    16
     Scherbatskoy v. Halliburton Co., 
    125 F.3d 288
    (5th Cir. 1997) (holding
    that an action arises under federal patent law, conferring exclusive federal
    jurisdiction, when resolution of state claims for breach of contract and fiduciary
    duty depends on application of federal patent laws).
    17
     Williams v. Briscoe, 
    137 S.W.3d 120
    , 124 (Tex. App.—Houston [1st
    Dist.] 2004, no pet.).
    18
     Alexander v. Turtur & Assocs., Inc., 
    146 S.W.3d 113
    , 117 (Tex. 2004).
    11
    timely plead and brief “experimental use” caused the dismissal of his patent
    infringement claims in the Patent Litigation.
    A federal question exists “only [in] those cases in which a well-pleaded
    complaint establishes either that federal patent law creates the cause of action or
    that the plaintiff’s right to relief necessarily depends on resolution of a substantial
    question of federal patent law.”19 The fact that treatment of a substantial federal
    question is necessary to the resolution of a state-law claim is not, however,
    sufficient to permit federal jurisdiction. “[T]he presence of a disputed federal issue
    [in a state cause of action] . . . [is] never necessarily dispositive.”20 Instead, “the
    question is, does a state-law claim necessarily raise a stated federal issue, actually
    disputed and substantial, which a federal forum may entertain without disturbing
    any   congressionally      approved    balance     of   federal   and    state   judicial
    responsibilities.”21 “In other words, federal question jurisdiction exists where (1)
    resolving a federal issue is necessary to resolution of the state-law claim; (2) the
    federal issue is actually disputed; (3) the federal issue is substantial; and (4) federal
     Christianson v. Colt Indus. Operating Corp., 
    486 U.S. 800
    , 809, 108 S.
    19
    Ct. 2166, 2174 (1988).
     Grable & Sons Metal Prods., Inc. v. Darue Eng’g & Mfg., 
    545 U.S. 20
    308, 314, 
    125 S. Ct. 2363
    , 2368 (2005); see Merrell Dow Pharms. Inc. v.
    Thompson, 
    478 U.S. 804
    , 813–14, 
    106 S. Ct. 3229
    , 3234–35 (1986).
    21
     
    Grable, 545 U.S. at 314
    , 125 S. Ct. at 2368.
    12
    jurisdiction will not disturb the balance of federal and state judicial responsibilities.” 22
    While the first and second elements of this test may be satisfied here, the third and
    fourth are not.
    The federal issue here is not substantial. Although significant to Minton’s
    claim, the issue of whether there was evidence of experimental use of the
    technology at issue is predominantly one of fact, with little or no precedential value.
    Therefore, resolution of the issue will not require “resort to the experience,
    solicitude, and hope of uniformity that a federal forum offers.”23 The courts of this
    state are perfectly capable of deciding cases such as this.
    Not only is the federal law issue insubstantial, but the exercise of federal
    jurisdiction over this state-law malpractice claim would disturb the balance between
    federal and state judicial responsibilities. “Legal malpractice has traditionally been
    the domain of state law, and federal law rarely interferes with the power of state
    authorities to regulate the practice of law.”24 To extend federal jurisdiction to every
    instance in which a lawyer commits alleged malpractice during the litigation of a
    22
     Singh v. Duane Morris LLP, 
    538 F.3d 334
    , 338 (5th Cir. 2008).
    23
     
    Grable, 545 U.S. at 312
    , 125 S. Ct. at 2367.
     
    Singh, 538 F.3d at 339
    ; see also Custer v. Sweeney, 
    89 F.3d 1156
    ,
    24
    1167 (4th Cir. 1996).
    13
    patent claim (or other federal law claim) would “constitute a substantial usurpation
    of state authority in an area in which states have traditionally been dominant.”25
    For these reasons, we hold that Minton’s legal malpractice claim does not
    “arise under” federal law.26
    In so holding, we decline to follow the Federal Circuit’s decisions in
    Immunocept and AMT for two reasons: First, the Federal Circuit’s holdings are not
    binding on this court. The Supreme Court of Texas has explained that: “While
    Texas courts may certainly draw upon the precedents of the Fifth Circuit, or any
    other federal or state court, in determining the appropriate federal rule of decision,
    they are obligated to follow only higher Texas courts and the United States
    Supreme Court.”27 Second, we believe the Federal Circuit misapplied United States
    Supreme Court precedent by disregarding the federalism analysis that the Supreme
    Court has applied to restrict the scope of federal “arising under” jurisdiction to a
    “special and small category” of cases where a substantial question of pure federal
    25
     
    Singh, 538 F.3d at 340
    .
    26
     Our holding should not be construed as suggesting that no legal
    malpractice claims involving patent litigation could possibly arise under federal
    law. In fact, it is possible that the federal interest in other legal malpractice
    cases would be sufficiently more substantial, such that federal jurisdiction would
    be justified. We hold only that federal jurisdiction does not extend to the legal
    malpractice claim before us.
     Penrod Drilling Corp. v. Williams, 
    868 S.W.2d 294
    , 296 (Tex. 1993)
    27
    (emphasis omitted); see also City of Carrollton v. Singer, 
    232 S.W.3d 790
    , 797
    n.6 (Tex. App.—Fort Worth 2007, pet. denied).
    14
    law is in dispute that has precedential value.28 According to the United States
    Supreme Court, claims that are “fact-bound and situation-specific,” such as the
    legal malpractice claim at issue in this case, do not fall within the scope of federal
    “arising under” jurisdiction.29 While this result may conflict with Federal Circuit
    decisions, we are obligated only to follow the rules for determining “arising under”
    jurisdiction established by the United States Supreme Court.
    We now turn to the merits.
     See, e.g., Empire Healthchoice Assurance, Inc. v. McVeigh, 
    547 U.S. 28
    677, 699–701, 
    126 S. Ct. 2121
    , 2136–37 (2006).
    29
     
    Id. at 701,
    126 S. Ct. at 2137. Minton’s reliance on the Fifth Circuit’s
    opinion in Scherbatskoy is misplaced for similar reasons. Scherbatskoy is
    distinguishable on the facts and was decided prior to the more recent United
    States Supreme Court decisions that adopted the federalism analysis that
    governs our decision here. Compare 
    Scherbatskoy, 125 F.3d at 291
    (finding
    federal “arising under” jurisdiction in breach of contract claim based solely on the
    conclusion that the patent issue “is a necessary element” to the resolution of the
    claim) with Empire, 547 U.S. at 
    701, 126 S. Ct. at 2137
    (“[I]t takes more than a
    federal element ‘to open the arising under door.’”) and 
    Grable, 545 U.S. at 313
    –14, 125 S. Ct. at 2367 (“[T]he federal issue will ultimately qualify for a
    federal forum only if federal jurisdiction is consistent with congressional
    judgment about the sound division of labor between state and federal courts.”).
    15
    V.   Standards of Review
    The trial court’s take-nothing summary judgment against Minton was
    rendered on both traditional and no-evidence motions for summary judgment filed
    by appellees.
    A.    Traditional Summary Judgment
    In reviewing a traditional summary judgment, the issue on appeal is whether
    the movant met the summary judgment burden by establishing that no genuine
    issue of material fact exists and that the movant is entitled to judgment as a matter
    of law.30 The burden of proof is on the movant, and all doubts about the existence
    of a genuine issue of material fact are resolved against the movant. 31 When
    reviewing a summary judgment, we take as true all evidence favorable to the
    nonmovant, and we indulge every reasonable inference and resolve any doubts in
    the nonmovant’s favor.32 Evidence that favors the movant’s position will not be
    considered unless it is uncontroverted.33
     Tex. R. Civ. P. 166a(c); Sw. Elec. Power Co. v. Grant, 
    73 S.W.3d 211
    ,
    30
    215 (Tex. 2002); City of Houston v. Clear Creek Basin Auth., 
    589 S.W.2d 671
    ,
    678 (Tex. 1979).
    31
     Sw. Elec. Power 
    Co., 73 S.W.3d at 215
    .
    32
     Valence Operating Co. v. Dorsett, 
    164 S.W.3d 656
    , 661 (Tex. 2005).
     Great Am. Reserve Ins. Co. v. San Antonio Plumbing Supply Co., 391
    
    33 S.W.2d 41
    , 47 (Tex. 1965).
    16
    A defendant who conclusively negates at least one essential element of a
    cause of action is entitled to summary judgment on that claim.34          Once the
    defendant produces sufficient evidence to establish the right to summary judgment,
    the burden shifts to the plaintiff to come forward with competent controverting
    evidence raising a genuine issue of material fact with regard to the element
    challenged by the defendant.35
    B.    No-Evidence Summary Judgment
    Rule 166a(i) of the Texas Rules of Civil Procedure governs no-evidence
    summary judgments.36 Under this rule, after an adequate time for discovery, the
    party without the burden of proof may, without presenting evidence, move for
    summary judgment on the ground that there is no evidence to support an essential
    element of the nonmovant’s claim or defense.37 The motion must specifically state
    the elements for which there is no evidence. 38 The trial court must grant the motion
     IHS Cedars Treatment Ctr. of DeSoto, Tex., Inc. v. Mason, 143
    
    34 S.W.3d 794
    , 798 (Tex. 2004).
    35
     Centeq Realty, Inc. v. Siegler, 
    899 S.W.2d 195
    , 197 (Tex. 1995).
    36
     Tex. R. Civ. P. 166a(i).
    37
     
    Id. 38 
    Id.; Johnson v. Brewer & Pritchard, P.C., 
    73 S.W.3d 193
    , 207 (Tex.
    2002).
    17
    unless the nonmovant produces summary judgment evidence that raises a genuine
    issue of material fact.39
    When reviewing a no-evidence summary judgment, we examine the entire
    record in the light most favorable to the nonmovant, indulging every reasonable
    inference and resolving any doubts against the motion.40 If the nonmovant brings
    forward more than a scintilla of probative evidence that raises a genuine issue of
    material fact, then a no-evidence summary judgment is not proper.41 We review a
    no-evidence summary judgment for evidence that would enable reasonable and
    fair-minded jurors to differ in their conclusions.42
    VI.   Analysis
    A.     The Purpose of the TEXCEN Lease was Commercial and There is No
    Evidence that the Lease was Primarily for Experimental Use
    The pivotal questions we must decide in reviewing the trial court’s summary
    judgment are: (1) whether the trial court correctly concluded that the TEXCEN
    Lease had a commercial purpose as a matter of law (2) and whether the trial court
    39
     See Tex. R. Civ. P. 166a(i) & cmt.; Sw. Elec. Power 
    Co., 73 S.W.3d at 215
    .
    40
     Sudan v. Sudan, 
    199 S.W.3d 291
    , 292 (Tex. 2006).
     Moore v. K Mart Corp., 
    981 S.W.2d 266
    , 269 (Tex. App.—San Antonio
    41
    1998, pet. denied).
     Hamilton v. Wilson, 
    249 S.W.3d 425
    , 426 (Tex. 2008) (citing City of
    42
    Keller v. Wilson, 
    168 S.W.3d 802
    , 822 (Tex. 2005)).
    18
    correctly found that there is no evidence to support Minton’s claim of an
    experimental purpose for the TEXCEN Lease. We conclude that both trial court
    rulings are correct.
    1.     The Commercial Purpose of the Lease was Established as a
    Matter of Law
    The TEXCEN Lease expressly states that Stark was leasing TEXCEN for
    commercial use. In its preamble, the lease provides that “[Stark] . . . wishes to
    lease TEXCEN from TISE for the purpose of opening brokerage accounts and
    executing trades for individuals using TEXCEN.” It further requires Stark to pay for
    the use of TEXCEN for three years (with an option of up to thirteen years) and
    warrants that TEXCEN will perform in a workmanlike manner. There is no language
    in the lease that indicates that the lease had an experimental purpose.
    In addition to the express language of the TEXCEN Lease, Minton offered
    deposition testimony in the Patent Litigation which established that the purpose of
    the lease was commercial:
    Q.    Okay. And they were—now, they were seeking—still seeking
    the regulatory approval, correct?
    A.     Yes, sir.
    Q.     But subject to that regulatory approval, what was
    contemplated was that Stark would set up a system using
    the TEXCEN software program and—to use it commercially,
    correct?
    A.     Yes, sir.
    19
    Q.     And—and that occurred beginning in March 1995, correct?
    A.     Yes, sir.
    Q.     And you expected to benefit financially from that
    arrangement, correct?
    A.     Yes, sir (emphasis added).
    Based on the language of the TEXCEN Lease and Minton’s own testimony
    establishing the commercial purpose of the lease, we hold that the trial court did not
    err in concluding that the TEXCEN Lease had a commercial purpose as a matter
    of law.
    2.     There is No Evidence that any Purpose of the TEXCEN Lease was
    Experimental
    a.    Minton’s Claim of an Alleged Experimental Purpose for the
    TEXCEN Lease Does not Relate to a Claimed Element of the
    ‘643 Patent
    The trial court concluded, as a matter of law, that the claims of the ‘643
    Patent do not require that the program work over a TCPIP or internet connection
    and, thus, any evidence of testing over a TCPIP or internet connection is legally
    irrelevant to show an experimental purpose for the TEXCEN Lease. We agree with
    this conclusion.
    Under settled patent law, the experimental use doctrine applies only to
    experimentation that relates to a claimed feature of the invention, either as
    20
    expressly stated in a claim or inherent to the subject matter of a claim.43 When
    evaluating whether a feature is claimed by an invention, courts look to details that
    are “specifically recited or necessary to the invention covered by the claims in
    suit.”44    For example, courts have held that testing for durability may negate
    application of the on sale bar even when durability is not specifically claimed in the
    patent, but only if durability is inherent to “the nature of the invention” based on “the
    claims’ reference to the subject matter.”45
    Therefore, our inquiry focuses on whether the attributes that Minton testifies
    were being tested—TEXCEN’s ability to process actual trades over an internet
    connection—relate to a claimed feature of the ‘643 Patent. If not, then Minton’s
     
    Electromotive, 417 F.3d at 1211
    (“It is important to recognize that this
    43
    court has limited experimentation sufficient to negate a pre-critical date public
    use or commercial sale to cases where the testing was performed to perfect
    claimed features, or, in a few instances like the case here, to perfect features
    inherent to the claimed invention.”); W. Marine Elecs., Inc. v. Furuno Elec. Co.,
    
    764 F.2d 840
    , 847 (Fed. Cir. 1985) (“The trial court properly recognized that
    testing or experimentation performed with respect to non-claimed features of the
    device does not show that the invention was the subject of experimentation.“); In
    re Theis, 
    610 F.2d 786
    , 793 (C.C.P.A. 1979) (“It is settled law that the
    experimental sale exception does not apply to experiments performed with
    respect to nonclaimed features of an invention.”).
     Gould Inc. v. United States, 
    579 F.2d 571
    , 582 (Ct. Cl. 1978); see also
    44
    Honeywell Int’l. Inc. v. Universal Avionics Sys. Corp., 
    488 F.3d 982
    , 998 (Fed.
    Cir. 2007).
     EZ 
    Dock, 276 F.3d at 1351
    –53; see also Kolmes v. World Fibers
    45
    Corp., 
    107 F.3d 1534
    , 1540 (Fed. Cir. 1997); Manville Sales Corp. v. Paramount
    Sys., Inc., 
    917 F.2d 544
    , 551 (Fed. Cir. 1990).
    21
    testimony regarding this testing will not, as a matter of law, support experimental
    use.46
    Minton contends that testing TEXCEN over the internet is a claimed feature
    of the ‘643 Patent because the patent claims that it will work over “a public
    communication network” and that the internet is one such network. However, the
    patent specifies that “[t]he method by which users . . . communicate with [the]
     Minton asserts that the trial court committed error by using this
    46
    standard because experimental use is supported by any testing needed to
    convince the inventor that the invention is capable of performing its intended
    purpose in its intended environment. See 
    Gould, 579 F.2d at 583
    . Testing,
    however, only supports experimental use in instances where it expressly or
    inherently relates to a claimed feature. See, e.g., 
    Kolmes, 107 F.3d at 1540
    (holding testing for durability established experimental use because, based on
    “the preamble of claim 1 [of the patent],” an “inherent feature” of the invention is
    “the ability to withstand use in an environment such as a meat-packing plant with
    repeated laundering”); 
    Gould, 579 F.2d at 582
    (holding experimental use
    exception did not apply where “the work done was not directed toward the
    invention covered by the claims in suit, the overall engine configuration, but was
    directed toward scaling-up [increasing the output horsepower of] the engine and
    checking and adjusting the performance of component parts”). Additionally,
    there is no probative value to an inventor’s subjective characterizations of an
    offer for sale as experimental when first expressed only after a patent
    infringement action has been filed. See, e.g., Cargill, Inc. v. Canbra Foods, Ltd.,
    
    476 F.3d 1359
    , 1370 (Fed. Cir. 2007); 
    Electromotive, 417 F.3d at 1212
    ; D.L.
    Auld Co. v. Chroma Graphics Corp., 
    714 F.2d 1144
    , 1150 (Fed. Cir. 1983) (“[I]f a
    mere allegation of experimental intent were sufficient, there would rarely if ever
    be room for summary judgment based on a true ‘on sale’ defense under 35
    U.S.C. § 102(b).”). Subjective assertions of experimental use in Minton’s
    deposition and affidavit testimony generated in the Patent Litigation, including
    his affidavit testimony that the primary purpose of the TEXCEN Lease was “to be
    able to test and further develop the program,” are not evidence of experimental
    use absent supporting objective relevant evidence predating the Patent
    Litigation.
    22
    server . . . is not important, as the present invention simply requires that the users
    be able to send and receive information to [the] server.” 47 The patent also provides
    a nonexclusive list of communication methods that may be employed, including
    “public telephone lines,” “cable modems, local area networks [LANs], wireless
    communications, fiber optics lines, and others.”48
    Because the express language of the ‘643 Patent conclusively demonstrates
    that performance over the internet is not inherent to any claimed feature of the
    patent, we hold that the trial court did not err in concluding that there is no evidence
    to support Minton’s claims of experimental use because evidence of testing over
    the internet is legally irrelevant to show an experimentation purpose for the
    TEXCEN Lease.
    47
     ‘643 Patent, col. 7, ll. 25–28.
    48
     
    Id. at col.
    7, ll. 20, 24–25.
    23
    b.    Even Assuming Testing Over the Internet Relates to a
    Claimed Feature of the ‘643 Patent, There is no Evidence to
    Support Minton’s Claim that the Purpose of the TEXCEN
    Lease was Experimental
    The trial court found that, assuming Minton’s evidence of testing relating to
    a TCPIP or internet connection is relevant, Minton still did not produce sufficient
    evidence to raise a genuine issue of material fact to support his claim of
    experimental use.49      We agree with the trial court’s finding because Minton
    presented no probative evidence that Stark was actually aware that the purpose of
    the offer for sale was primarily experimental when the lease was executed. 50
    The determination of experimental use is an objective inquiry based on the
    facts surrounding the transaction.51 Courts have considered a number of objective
    factors when making an experimental use determination, including, but not limited
    to:
    (1) the necessity for public testing, (2) the amount of control over the
    experiment retained by the inventor, (3) the nature of the invention, (4)
    the length of the test period, (5) whether payment was made, (6)
    whether there was a secrecy obligation, (7) whether records of the
    49
     If there is no evidence that the TEXCEN Lease had an experimental
    purpose, then the lease could not have been “primarily” experimental in purpose
    so as to negate the on sale bar.
    50
     See Cincinnati Life Ins. Co. v. Cates, 
    927 S.W.2d 623
    , 625 (Tex.
    1996) (when trial court grants summary judgment on fewer than all grounds
    asserted, appellate court may affirm summary judgment on other grounds
    properly raised in the trial court).
    51
     
    Electromotive, 417 F.3d at 1210
    ; Allen Eng’g 
    Corp., 299 F.3d at 1354
    .
    24
    experiment were kept, (8) who conducted the experiment, (9) the
    degree of commercial exploitation during testing, (10) whether the
    invention reasonably requires evaluation under actual conditions of
    use, (11) whether testing was systematically performed, (12) whether
    the inventor continually monitored the invention during testing, and
    (13) the nature of contacts made with potential customers. 52
    With regard to the last factor — nature of contacts made with potential
    customers — the Federal Circuit has held that a customer’s awareness that the
    purpose of the sale was for experimental use is a “critical attribute of
    experimentation.”53 If an inventor fails to communicate to a customer that the sale
    of the invention was made in pursuit of experimentation, then the customer, as well
    as the general public, can only view the sale as a normal commercial transaction.54
    “[An inventor’s] failure to communicate to any of the purchasers or prospective
    purchasers of his device that the sale or offering was for experimental use is fatal
    to his case.”55 In other words, customer awareness of the sale or offering’s
    experimental purpose is dispositive.56
     Allen Eng’g 
    Corp., 299 F.3d at 1353
    ; see also Electromotive, 
    417 F.3d 52
    at 1210.
    53
     
    Electromotive, 417 F.3d at 1214
    .
    54
     In re Dybel, 
    524 F.2d 1393
    , 1401 (C.C.P.A. 1975); see also Paragon
    Podiatry 
    Lab., 984 F.2d at 1186
    .
    55
     In re 
    Dybel, 524 F.2d at 1401
    .
    56
     See, e.g., Lough v. Brunswick Corp., 
    86 F.3d 1113
    , 1120 (Fed. Cir.
    1996), cert. denied, 
    522 U.S. 806
    (1997); In re Hamilton, 
    882 F.2d 1576
    , 1581
    (Fed. Cir. 1989).
    25
    In his deposition testimony, Minton admitted that he never told Stark that the
    purpose of the TEXCEN Lease was to develop, test, or conduct experimentation
    on TEXCEN. Indeed, the summary judgment record contains no evidence showing
    that Stark was aware at the time the lease was executed that it was for
    experimental purposes. At most, the evidence on which Minton relies to establish
    Stark’s awareness of the lease’s experimental purpose merely shows that Stark
    knew at the time the lease was executed that TEXCEN was under development and
    that it may require further testing. This evidence does not prove that the purpose
    of the lease was experimental.57 Nor does Minton’s subjective characterization of
    the purpose of the lease made after the Patent Litigation constitute sufficient
    probative evidence to establish that Stark was aware of any alleged experimental
    use.58
    Because there is no evidence that Stark was aware that the actual purpose
    of the TEXCEN Lease was experimental, we hold that, even assuming testing over
     Allen Eng’g 
    Corp., 299 F.3d at 1354
    ; see also 
    Scaltech, 178 F.3d at 57
    1384 n.1 (“Commercial exploitation, if not incidental to the primary purpose of
    experimentation, will result in an on sale bar, even if the invention was still in its
    experimental stage.”).
     See, e.g., 
    Cargill, 476 F.3d at 1370
    ; 
    Electromotive, 417 F.3d at 1212
    ,
    58
    1214; 
    Petrolite, 96 F.3d at 1427
    ; Paragon Podiatry 
    Lab., 984 F.2d at 1186
    ;
    Sinskey v. Pharmacia Ophthalmics, Inc., 
    982 F.2d 494
    , 499 (Fed. Cir. 1992),
    cert. denied, 
    508 U.S. 912
    (1993); LaBounty Mfg., Inc. v. United States Int’l
    Trade Comm’n, 
    958 F.2d 1066
    , 1071–72 (Fed. Cir. 1992); D.L. Auld 
    Co., 714 F.2d at 1150
    .
    26
    the internet is relevant to a claimed element of the ‘643 Patent, the trial court did not
    err in finding that Minton failed to raise a genuine issue of material fact on his claim
    that the TEXCEN Lease had an experimental purpose. Therefore, as a matter of
    law, the lease was not primarily experimental in purpose and Minton has no
    defense to the on sale bar under the experimental use doctrine.
    VII.   Conclusion
    In sum, we hold that Minton’s legal malpractice claim does not “arise under”
    federal law, and that we have jurisdiction over this appeal. We further hold that the
    trial court did not err in granting appellees’ traditional motion for summary judgment
    based on its conclusion that the TEXCEN Lease had a commercial purpose as a
    matter of law, and in granting appellees’ no-evidence motion for summary judgment
    on the ground that Minton failed to produce sufficient relevant evidence to raise a
    genuine issue of material fact to support his claim of experimental use.59 The trial
    court’s summary judgment is affirmed.
    JOHN CAYCE
    CHIEF JUSTICE
    PANEL: CAYCE, C.J.; GARDNER and WALKER, JJ.
     In light of these holdings, we need not reach Minton’s other issues or
    59
    appellees’ cross-point. See Tex. R. App. P. 47.1.
    27
    WALKER, J. filed a dissenting opinion.
    DELIVERED: October 8, 2009
    28
    COURT OF APPEALS
    SECOND DISTRICT OF TEXAS
    FORT WORTH
    NO. 2-06-443-CV
    VERNON F. MINTON                                                APPELLANT
    V.
    JERRY W. GUNN, INDIVIDUALLY;                                    APPELLEES
    WILLIAMS SQUIRE & WREN, LLP; JAMES
    E. WREN, INDIVIDUALLY; SLUSSER &
    FROST, L.L.P.; WILLIAM C. SLUSSER,
    INDIVIDUALLY; SLUSSER WILSON &
    PARTRIDGE, L.L.P; AND MICHAEL E.
    WILSON, INDIVIDUALLY
    ------------
    FROM THE 48TH DISTRICT COURT OF TARRANT COUNTY
    ------------
    DISSENTING OPINION
    ------------
    I. INTRODUCTION
    I respectfully dissent.   Because the federal courts possess exclusive
    jurisdiction over Appellant Vernon F. Minton’s legal malpractice suit against
    Appellees Jerry W. Gunn, individually; Williams Squire & Wren, LLP; James E.
    Wren, individually; Slusser & Frost, L.L.P.; William C. Slusser, individually; Slusser
    Wilson & Partridge, L.L.P.; and Michael E. Wilson, individually, I would grant
    Minton’s motion to dismiss, vacate the trial court’s order granting summary
    judgment for Appellees, and remand the case to the trial court for disposition in
    accordance with this opinion.
    II. FACTS
    A. Minton’s Patent Infringement Suit in Federal Court
    In the underlying litigation giving rise to Minton’s legal malpractice claim,
    Minton sued NASD and NASDAQ Stock Market, Inc. in the United States District
    Court for the Eastern District of Texas for patent infringement. 1 The federal trial
    court granted NASD and NASDAQ’s “Motion for Summary Judgment that [the ’643
    Patent] is Invalid under the ‘On Sale’ Bar Provision of 35 U.S.C. § 102(b).” See 35
    U.S.C.A. § 102(b) (West 2001). The trial court granted summary judgment for
    NASD and NASDAQ based on the on sale bar rule, and the Court of Appeals for
    the Federal Circuit affirmed the trial court’s summary judgment. See Minton v. Nat’l
    Ass’n of Sec. Dealers, Inc., 
    336 F.3d 1373
    , 1381 (Fed. Cir. 2003).
    B. Minton’s Legal Malpractice Suit in State Court
    Minton subsequently filed a legal malpractice suit in state court; his original
    petition asserted that Appellees, his attorneys in the underlying federal patent
    1
     Minton alleged that NASD and NASDAQ have “infringed and continued
    to infringe claims 1, 2, 3 and 4” of U.S. Patent No. 6,014,643 (the ’643 Patent).
    2
    infringement suit, negligently did not plead or brief the experimental use exception
    to the on sale bar rule in an amended petition, in Minton’s summary judgment
    response, or in the response to the trial court’s request for briefing. These
    allegations are the sole basis for Minton’s legal malpractice suit; he pleaded that
    Appellees owed a duty to represent him in his patent infringement suit within the
    applicable standard of care and that they breached their duty to him by “[f]ailing to
    timely plead and brief the experimental use defense.”
    Appellees filed two joint combined traditional and no-evidence motions for
    summary judgment in Minton’s state legal malpractice action asserting that “the
    record establishes as a matter of law that Defendants’ conduct did not proximately
    cause Minton’s alleged damages because Minton would not have been able to
    successfully defeat the on sale bar either at the summary judgment stage or at
    trial.” The trial court granted both Appellees’ joint motions for summary judgment.
    This appeal followed, and Minton filed a motion to dismiss, alleging that the federal
    courts possess exclusive jurisdiction over his legal malpractice suit.
    III. THE LAW CONCERNING SECTION 1338 JURISDICTION
    The United States Code provides that “[t]he district courts shall have original
    jurisdiction of any civil action arising under any Act of Congress relating to patents
    . . . . Such jurisdiction shall be exclusive of the courts of the states in patent . . .
    3
    cases.” 28 U.S.C.A. § 1338(a) (West 2006).2 The United States Supreme Court
    has for nearly 100 years recognized that in certain cases federal question
    jurisdiction will lie over state law claims that implicate significant federal issues.
    Grable & Sons Metal Prods., Inc. v. Darue Eng’g & Mfg., 
    545 U.S. 308
    , 312, 125 S.
    Ct. 2363, 2367 (2005).
    A significant federal issue is implicated when a well-pleaded complaint
    establishes that the plaintiff’s right to relief necessarily depends on resolution of a
    substantial question of federal patent law in that federal law is a necessary element
    of the well-pleaded complaint. Christianson v. Colt Indus. Operating Corp., 
    486 U.S. 800
    , 809, 
    108 S. Ct. 2166
    , 2174 (1988). The well-pleaded complaint rule is
    the starting point in analyzing Section 1338 jurisdiction in suits involving patents.
    See, e.g., Caterpillar, Inc. v. Williams, 
    482 U.S. 386
    , 392, 
    107 S. Ct. 2425
    , 2429
    (1987). Under this “well-pleaded complaint” rule, whether the claim arises under
    federal patent law “‘must be determined from what necessarily appears in the
    plaintiff’s statement of his own claim . . . unaided by anything alleged in anticipation
    or avoidance of defenses which it is thought the defendant may interpose.’”
    
    Christianson, 486 U.S. at 809
    , 108 S. Ct. at 2174 (quoting Taylor v. Anderson, 
    234 U.S. 74
    , 75–76, 
    34 S. Ct. 724
    , 724 (1914)). The complaint must do more than
    demonstrate that a question of federal patent law is “lurking in the background.”
    2
     Hereinafter referred to as “Section 1338.”
    4
    Franchise Tax Bd. of State of Cal. v. Constr. Laborers Vacation Trust for S. Cal.,
    
    463 U.S. 1
    , 12, 
    103 S. Ct. 2841
    , 2847 (1983). A complaint successfully establishes
    that a plaintiff’s right to relief necessarily depends on a substantial question of
    patent law and that federal law is a necessary element of the well-pleaded
    complaint when from the plaintiff’s pleading, it appears that some right or privilege
    will be defeated by one construction or sustained by the opposite construction of
    patent laws. 
    Christianson, 486 U.S. at 807
    –08, 108 S. Ct. at 2173. 3 But a pleaded
    claim supported by alternative theories in the complaint may not form the basis for
    Section 1338 jurisdiction unless patent law is essential to each of those theories.
    
    Id. at 812,
    108 S. Ct. at 2175–76 (recognizing, in applying well-pleaded complaint
    doctrine, that although the patent issue could be an element of the plaintiff’s
    3
     See also Univ. Of W. Va. Bd. of Trs. v. VanVoorhies, 
    278 F.3d 1288
    ,
    1295 (Fed. Cir. 2002) (holding Section 1338 jurisdiction existed over state law
    claim alleging breach of duty to assign a patent because claim required
    resolution of the disputed patent application); U.S. Valves, Inc. v. Dray, 
    212 F.3d 1368
    , 1372 (Fed. Cir. 2000) (holding Section 1338 jurisdiction existed over state
    law breach of contract claim requiring proof of patent infringement); Hunter
    Douglas, Inc. v. Harmonic Design, Inc., 
    153 F.3d 1318
    , 1329 (Fed. Cir. 1998)
    (holding Section 1338 jurisdiction existed over state law claim of injurious
    falsehood when plaintiff was required to prove invalidity of patent), overruled in
    part on other grounds by Midwest Indus., Inc. v. Karavan Trailers, Inc., 
    175 F.3d 1356
    , 1358–59 (Fed. Cir. 1999), and cert. denied, 
    525 U.S. 1143
    (1999);
    Scherbatskoy v. Halliburton Co., 
    125 F.3d 288
    , 291 (5th Cir. 1997) (holding
    Section 1338 jurisdiction existed over state law breach of contract claim when
    plaintiff was required to prove patent infringement); Additive Controls &
    Measurement Sys., Inc. v. Flowdata, Inc., 
    986 F.2d 476
    , 477–78 (Fed. Cir. 1993)
    (holding Section 1338 jurisdiction existed over state law business disparagement
    claim that required proof of patent non-infringement).
    5
    monopolization antitrust theory and plaintiff’s group-boycott antitrust theory,
    plaintiff’s complaint also pleaded reasons completely unrelated to the provisions
    and purposes of federal patent law why the plaintiff might be entitled to the relief
    sought so that plaintiff’s claims did not “arise under” Section 1338).
    In determining whether federal question jurisdiction exists, in addition to
    examining whether a well-pleaded complaint establishes that the plaintiff’s right to
    relief necessarily depends on resolution of a substantial question of federal patent
    law in that federal law is a necessary element of the well-pleaded complaint, courts
    must also conduct a federalism analysis. 
    Grable, 545 U.S. at 313
    –14, 125 S. Ct.
    at 2367–68. That is, courts must also examine whether federal court jurisdiction
    over a state claim implicating a substantial question of federal law is consistent with
    congressional judgment regarding the proper division of labor between state and
    federal courts. 
    Id. 125 S. Ct.
    at 2367. Stated another way, courts must inquire
    whether a federal forum may entertain the state claim raising a disputed, substantial
    federal issue without disturbing any congressionally approved balance of federal
    and state judicial responsibilities. Id. at 
    314, 125 S. Ct. at 2368
    . When Congress
    has not provided a federal, private remedy for the violation of a particular federal
    statute, the presence of an issue concerning that statute as an element of a state
    tort claim is not ordinarily considered “substantial” enough to confer federal
    question jurisdiction. See Franchise Tax 
    Bd., 463 U.S. at 21
    –22, 103 S. Ct. at 2852
    (holding federal question jurisdiction did not exist over a declaratory judgment suit
    6
    brought by state taxing authorities concerning the application of a state statute to
    an ERISA qualified trust); see also Merrell Dow Pharms. Inc. v. Thompson, 
    478 U.S. 804
    , 814, 
    106 S. Ct. 3229
    , 3235 (1986) (holding federal question jurisdiction
    did not exist over state tort claim that pharmaceutical company had misbranded
    drug Bendectin in violation of Federal Food, Drug, and Cosmetic Act).
    IV. SECTION 1338 JURISDICTION OVER MINTON’S LEGAL MALPRACTICE CLAIM
    A. Minton’s Well-Pleaded Complaint
    Starting with a well-pleaded complaint analysis, Minton’s petition does
    establish that his right to relief in his state legal malpractice suit necessarily
    depends on resolution of a substantial question of federal patent law.             See
    
    Christianson, 486 U.S. at 809
    , 108 S. Ct. at 2174. As Appellees and the Majority
    Opinion acknowledge, to prevail in his legal malpractice claim, Minton must prove
    a “suit within a suit.” See Alexander v. Turtur Assocs., Inc., 
    146 S.W.3d 113
    , 117
    (Tex. 2004) (articulating suit within a suit requirement). That is, to prevail when the
    asserted legal malpractice involves the results of prior litigation, the plaintiff bears
    the additional burden of proving that, “but for” the attorney’s breach of duty, he
    would have won in the underlying litigation and would have been entitled to
    judgment. See, e.g., Schlager v. Clements, 
    939 S.W.2d 183
    , 186–87 (Tex.
    App.—Houston [14th Dist.] 1996, writ denied).
    7
    Turning specifically to Minton’s original pleading, he asserted one cause of
    action against Appellees—negligence. He asserted as the sole basis for his
    negligence pleading one theory of negligence by Appellees—the failure to timely
    plead and brief the experimental use exception in response to Appellees’ assertion
    of the on sale bar rule. Thus, in his state legal malpractice claim, Minton must
    prove that “but for” Appellees’ alleged negligence, he would have prevailed on
    every element of his patent infringement suit against NASD and NASDAQ,
    including application of the experimental use exception to the on sale bar rule and
    damages from NASD and NASDAQ’s alleged infringement and continued
    infringement of claims 1, 2, 3, and 4 of the ’643 Patent.
    B. A Disputed, Substantial Issue of Federal Patent Law
    When a state legal malpractice claim requires the hypothetical adjudication
    of the merits of an underlying federal patent infringement lawsuit—that is, trial of the
    patent infringement suit within the legal malpractice suit—the legal malpractice case
    presents a disputed, substantial question of federal patent law conferring Section
    1338 jurisdiction on the federal courts. See, e.g., Air Measurement Techs., Inc. v.
    Akin Gump Strauss Hauer & Feld, L.L.P., 
    504 F.3d 1262
    , 1272–73 (Fed. Cir. 2007) 4
    (holding federal courts possessed exclusive Section 1338 jurisdiction over Texas
    state legal malpractice claim stemming from underlying federal patent infringement
    4
     Hereinafter referred to as “AMT.”
    8
    suit); Immunocept, LLC v. Fulbright & Jaworski, LLP, 
    504 F.3d 1281
    , 1284 (Fed.
    Cir. 2007) (same, stemming from underlying claims for patent infringement,
    comparison of patent application, and patent scope). That is, when the plaintiff
    must plead and prove his entire underlying patent infringement suit to satisfy the
    “but for” causation requirement of his state legal malpractice claim, the state legal
    malpractice claim presents a disputed, substantial issue of federal patent law. See
    
    AMT, 504 F.3d at 1272
    (explaining that “patent infringement is disputed, for there
    is no concession by Akin Gump that the [defendants] infringed AMT’s patents, and
    the issue is substantial, for it is a necessary element of the malpractice case”);
    
    Immunocept, 504 F.3d at 1285
    (holding that “[b]ecause it is the sole basis of
    [plaintiff’s state law legal malpractice claim], the claim drafting error is a necessary
    element of the malpractice cause of action” and triggers Section 1338 jurisdiction).
    Numerous courts have followed the holdings of AMT and Immunocept; federal
    courts have denied motions to remand state legal malpractice claims stemming
    from underlying patent litigation and state courts have dismissed such actions,
    holding Section 1338 jurisdiction existed.5
    5
     See, e.g., Tomar Elecs., Inc. v. Watkins, No. 2:09-cv-00170-PHX-ROS,
    
    2009 WL 2222707
    , at *1–2 (D. Ariz. July 23, 2009) (order on motion to remand)
    (holding federal courts possessed exclusive Section 1338 jurisdiction over state
    law legal malpractice stemming from patent infringement suit); see also, e.g.,
    LaBelle v. McGonagle, No. 07-12097-GAO, 
    2008 WL 3842998
    , at *2–4 (D.
    Mass. Aug. 15, 2008) (opinion and order, not reported) (same, stemming from
    negligent failure to file patent application); Byrne v. Wood, Herron & Evans, LLP,
    No. 2: 08-102-DCR, 
    2008 WL 3833699
    , at *4–5 (E.D. Ky. Aug. 13, 2008) (mem.
    9
    In summary, it is clear from Minton’s legal malpractice pleading that his right
    to recover from Appellees in his legal malpractice suit will be defeated by one
    construction or sustained by the opposite construction of the patent laws
    concerning the on sale bar rule, concerning the experimental use exception, and
    ultimately concerning NASD’s and the NASDAQ’s alleged infringement to claims
    1, 2, 3 and 4 of the ’643 Patent.6 See 
    Christianson, 486 U.S. at 809
    , 108 S. Ct. at
    2174. Minton pleaded no alternative “theories” of recovery in his legal malpractice
    suit—the sole allegation of negligence against Appellees is that in Minton’s patent
    op. and order, not reported) (holding federal courts possessed exclusive Section
    1338 jurisdiction over state legal malpractice claim stemming from patent
    infringement suit); Lockwood v. Sheppard, Mullin, Richter & Hampton, 93 Cal.
    Rptr. 3d 220, 228–29 (Cal. Ct. App. 2009) (holding federal courts possessed
    exclusive Section 1338 jurisdiction over state law claims stemming from
    opposing attorney’s alleged action in obtaining patent reexamination); TattleTale
    Portable Alarm Sys. v. Calfee, Halter & Griswold, L.L.P., No. 08AP-693, 
    2009 WL 790314
    , at *4–5 (Ohio Ct. App. Mar. 26, 2009) (holding federal courts
    possessed exclusive Section 1338 jurisdiction over state law legal malpractice
    claim stemming from failure to pay patent maintenance fees or to seek revival of
    patent).
    6
     Both the on sale bar rule and the experimental use exception to the
    application of the on sale bar rule are part and parcel of Minton’s patent
    infringement lawsuit. See 35 U.S.C.A. § 102(b); Allen Eng’g Corp. v. Bartell
    Indus., Inc., 
    299 F.3d 1336
    , 1353 (Fed. Cir. 2002). They are not stand-alone
    doctrines or claims that may be plucked from a federal patent infringement
    lawsuit and, somehow, not present substantial issues of federal patent law when
    a patent infringement lawsuit itself presents a substantial question of federal
    patent law triggering Section 1338 jurisdiction. See 28 U.S.C.A. § 1338(a)
    (providing exclusive, original federal court jurisdiction over “any civil action
    arising under any Act of Congress relating to patents”); 
    AMT, 504 F.3d at 1270
    (recognizing that in the case-within-a-case context the on sale bar rule is “not the
    sort of jurisdiction defeating defense[] contemplated by Christianson”).
    10
    infringement suit they negligently failed to plead and brief the experimental use
    exception after NASD and NASDAQ moved for summary judgment on the basis of
    the on sale bar rule. Thus, application of the well-pleaded complaint doctrine and
    examination of whether Minton’s right to relief in his state legal malpractice suit
    necessarily depends on resolution of a substantial question of federal patent law
    both compel the conclusion that Minton’s state legal malpractice claim raises a
    disputed, substantial issue of federal patent law. See 
    AMT, 504 F.3d at 1269
    (holding, “[b]ecause proof of patent infringement is necessary to show AMT would
    have prevailed in the prior litigation, patent infringement is a ‘necessary element’
    of AMT’s malpractice claim and therefore apparently presents a substantial
    question of patent law conferring § 1338 jurisdiction”); 
    Immunocept, 504 F.3d at 1285
    (recognizing “a determination of patent infringement serves as the basis of §
    1338 jurisdiction over related state law claims”); see also 
    Christianson, 486 U.S. at 809
    , 108 S. Ct. at 2174; accord Marsh v. Austin-Fort Worth Coca-Cola Bottling Co.,
    
    744 F.2d 1077
    , 1079 (5th Cir. 1984) (holding Court of Appeals for the Federal
    Circuit possessed exclusive jurisdiction over summary judgment granted by federal
    district court for defendants on the basis that plaintiff “lost his patent rights” under
    35 U.S.C. § 102—the on sale bar rule—by displaying his invention at a convention
    before he applied for a patent even though plaintiff asserted state law claims and
    filed in federal court based on diversity of citizenship).
    C. Disagreement with the Majority Opinion’s Federal Question Analysis
    11
    The Majority Opinion holds that in Minton’s legal malpractice claim “the
    federal issue is insubstantial.” To reach this holding, despite the plethora of case
    law specifically addressing Section 1338 jurisdiction in state claims alleging legal
    malpractice during federal patent litigation,7 the Majority Opinion chooses to follow
    Singh v. Duane Morris, L.L.P, 
    538 F.3d 334
    , 338 (5th Cir. 2008). Singh is a Fifth
    Circuit case in which legal malpractice was alleged to have occurred during
    trademark litigation. 
    Id. The Singh
    opinion itself limited its holding to Section 1338
    jurisdiction in suits alleging malpractice during trademark litigation and expressly
    declined to extend its holding to suits alleging malpractice during patent litigation.
    The Fifth Circuit stated,
    It is possible that the federal interest in patent cases is sufficiently
    more substantial, such that it might justify federal jurisdiction. But we
    need not decide the question before the Federal Circuit [in AMT],
    because it is not before us. We conclude only that jurisdiction does
    not extend to malpractice claims involving trademark suits like this one.
    
    Id. at 340.
    I cannot agree with the Majority Opinion that the Singh opinion, having
    expressly declined to extend its holding to malpractice claims involving patent suits,
    has any application to the Section 1338 jurisdictional analysis of Minton’s
    malpractice claim involving a patent suit.
    D. Federalism Analysis
    7
     See, e.g., 
    AMT, 504 F.3d at 1272
    ; 
    Immunocept, 504 F.3d at 1285
    ; see
    also Tomar Elecs., Inc., 
    2009 WL 2222707
    , at *1–2; LaBelle, 
    2008 WL 3842998
    ,
    at *2–4; Byrne, 
    2008 WL 3833699
    , at*4–5; TattleTale Portable Alarm Sys., 
    2009 WL 790314
    , at *4–5.
    12
    A determination that a state law claim presents a disputed, substantial issue
    of federal patent law does not end a Section 1338 jurisdictional query. 
    Grable, 545 U.S. at 314
    , 125 S. Ct. at 2367. As previously mentioned, courts must also
    examine whether federal court jurisdiction over a state claim implicating a
    substantial question of federal law is consistent with congressional judgment
    regarding the proper division of labor between state and federal courts. Id. at 
    314, 125 S. Ct. at 2368
    .
    Moving to the required examination of whether a federal court’s exercise of
    subject matter jurisdiction over Minton’s state legal malpractice claim is consistent
    with congressional judgment regarding the proper division of labor between state
    and federal courts, the answer is clearly that it is. See id. at 
    314, 125 S. Ct. at 2368
    . As recognized by the Court of Appeals for the Federal Circuit in determining
    that Section 1338 jurisdiction existed over a Texas legal malpractice claim
    stemming from an underlying patent infringement suit—like Minton’s,
    There is a strong federal interest in the adjudication of patent
    infringement claims in federal court because patents are issued by a
    federal agency. The litigants will also benefit from federal judges who
    have experience in claim construction and infringement matters. See
    
    Grable, 545 U.S. at 315
    , 
    125 S. Ct. 2363
    ; see also Lacks Indus., Inc.
    v. McKechnie Vehicle Components USA, Inc., 
    322 F.3d 1335
    , 1341
    (Fed. Cir. 2003) (stating that patent infringement involves a two-step
    process where the court first determines the scope and meaning of the
    asserted claims and then compares the construed claims to the
    accused product). Under these circumstances, patent infringement
    justifies “resort to the experience, solicitude, and hope of uniformity
    that a federal forum offers on federal issues.” 
    Grable, 545 U.S. at 312
    ,
    
    125 S. Ct. 2363
    . In § 1338, Congress considered the federal-state
    13
    division of labor and struck a balance in favor of this court’s
    entertaining patent infringement. For us to conclude otherwise would
    undermine Congress’s expectations.
    
    AMT, 504 F.3d at 1272
    . Likewise, in Immunocept, the Court of Appeals for the
    Federal Circuit reiterated that Congress’s intent to remove non-uniformity in patent
    law, as evidenced by its enactment of the Federal Courts Improvement Act of 1982,
    was further indicium that Section 1338 jurisdiction existed over a Texas state legal
    malpractice claim stemming from attorneys’ alleged negligent claim drafting in a
    patent 
    application. 504 F.3d at 1285
    . For the reasons articulated in the AMT and
    the Immunocept opinions, by enacting Section 1338, Congress considered the
    federal-state division of labor and struck a balance in favor of the federal courts for
    patent infringement issues. 
    AMT, 504 F.3d at 1272
    ; 
    Immunocept, 504 F.3d at 1285
    .
    Minton’s state suit, unlike the state litigation Franchise Tax Board and Merrell
    Dow Pharmaceutical, Inc., is not based on a violation of a federal statute for which
    Congress has provided no private federal remedy. See Franchise Tax 
    Bd., 463 U.S. at 21
    –22, 103 S. Ct. at 2852 (ERISA); Merrell Dow Pharms. 
    Inc., 478 U.S. at 814
    , 106 S. Ct. at 3235 (FDCA). Minton’s suit is based on alleged malpractice
    during the pursuit of an authorized, private, exclusively federal remedy for patent
    infringement. See 28 U.S.C.A. § 1338(a) (granting federal district courts exclusive
    jurisdiction over patent cases). In fact, Minton must prove his entire private, federal
    cause of action for patent infringement as an element of his state law claim. Thus,
    14
    a federalism analysis of Minton’s state legal malpractice claim weighs in favor of the
    congressional intent expressed in Section 1338 that federal courts exercise original,
    exclusive jurisdiction over patent infringement issues. See 
    AMT, 504 F.3d at 1272
    ;
    
    Immunocept, 504 F.3d at 1285
    .
    E. Disagreement with the Majority Opinion’s Federalism Analysis
    The Majority Opinion holds that “the exercise of federal jurisdiction over this
    [Minton’s] state-law malpractice claim would disturb the balance between federal
    and state judicial responsibilities.” Majority Op. at 13. In reaching this conclusion,
    the Majority Opinion expressly declines to follow AMT’s and Immunocept’s
    federalism analysis for three reasons. First, the Majority Opinion chooses to give
    no precedential value to the jurisdictional determinations of the Court of Appeals for
    the Federal Circuit. Second, the Majority Opinion claims that in both AMT and
    Immunocept, the Court of Appeals for the Federal Circuit “misapplied United States
    Supreme Court precedent by disregarding the federalism analysis that the Supreme
    Court has applied to restrict the scope of federal ‘arising under jurisdiction.’”
    Majority Op. at 14–15. And third, the Majority Opinion summarily concludes that
    application of the on sale bar rule and the experimental use exception in Minton’s
    state legal malpractice suit are fact-bound and situation-specific issues. I cannot
    agree with any of these propositions.
    Concerning the precedential value to be given the jurisdictional
    determinations of the Court of Appeals for the Federal Circuit, the Majority Opinion
    15
    cites Penrod Drilling Corp. v. Williams, 
    868 S.W.2d 294
    (Tex. 1993), in support of
    its decision to give no precedential value to AMT’s and Immunocept’s federalism
    analysis.    Penrod Drilling, however, does not support the Majority Opinion’s
    position. Penrod Drilling actually holds that a court of appeals erred by following
    Fifth Circuit precedent and by summarily disregarding all contrary federal authority,
    just as the Majority Opinion here does by following the Fifth Circuit’s Singh decision
    and disregarding contrary federal authority. Majority Op. at 11–15; see 
    Singh, 868 S.W.2d at 296
    –97.
    Concerning the Majority Opinion’s conclusion that in both AMT and
    Immunocept the Court of Appeals for the Federal Circuit “misapplied United States
    Supreme Court precedent by disregarding the federalism analysis that the Supreme
    Court has applied [in Grable and Empire Healthchoice Assurance, Inc. v. McVeigh 8 ]
    to restrict the scope of federal ‘arising under jurisdiction,’” I simply cannot agree.
    Both AMT and Immunocept were decided in 2007 after Grable and Empire. See
    
    Grable, 545 U.S. at 308
    , 125 S. Ct. at 2363 (decided in 2005); 
    Empire, 547 U.S. at 677
    , 126 S. Ct. at 2136–37 (decided in 2006). Moreover, as set forth above, both
    AMT and Immunocept actually cite Grable and expressly discuss the federalism
    analysis required by Grable and Empire. See 
    AMT, 504 F.3d at 1272
    ; 
    Immunocept, 504 F.3d at 1285
    . The Majority Opinion does not posit exactly how the federalism
    8
     
    547 U.S. 677
    , 699–701, 
    126 S. Ct. 2121
    , 2137–37 (2006).
    16
    analysis of the Court of Appeals for the Federal Circuit is purportedly deficient in
    AMT and in Immunocept; no deficiency is apparent to me.
    In conducting the required federalism analysis in AMT, the Court of Appeals
    for the Federal Circuit expressly recognized “a strong federal interest in the
    adjudication of patent infringement claims in federal court because patents are
    issued by a federal agency.” 
    AMT, 504 F.3d at 1272
    ; see also 
    Immunocept, 504 F.3d at 1285
    . The Court of Appeals for the Federal Circuit explained that “[t]he
    litigants will also benefit from federal judges who have experience in claim
    construction and infringement matters.” 
    AMT, 504 F.3d at 1272
    (citing 
    Grable, 545 U.S. at 315
    , 125 S. Ct. at 2363); see also 
    Immunocept, 504 F.3d at 1285
    (citing
    Grable and explaining, “Litigants will benefit from federal judges who are used to
    handling these complicated rules”). The Court of Appeals for the Federal Circuit
    explicitly stated that a state claim requiring proof of patent infringement justifies
    “resort to the experience, solicitude, and hope of uniformity that a federal forum
    offers on federal issues.” 
    AMT, 504 F.3d at 1269
    ; see also 
    Immunocept, 504 F.3d at 1285
    (recognizing that the intent of Congress to remove non-uniformity in the
    patent laws via the enactment of the Federal Courts Improvement Act of 1982 is a
    further indication of federal question jurisdiction in a state legal malpractice suit
    requiring the proof of an entire underlying patent infringement lawsuit). The Court
    of Appeals for the Federal Circuit noted that “[i]n § 1338, Congress considered the
    federal-state division of labor and struck a balance in favor of this court’s
    17
    entertaining patent infringement.” 
    AMT, 504 F.3d at 1272
    ; 
    Immunocept, 504 F.3d at 1286
    . Finally, the Court of Appeals for the Federal Circuit in AMT held that “[f]or
    us to conclude otherwise would undermine Congress’s expectations.” 
    AMT, 504 F.3d at 1272
    . Thus, the Court of Appeals for the Federal Circuit in AMT and in
    Immunocept did conduct the required federalism analysis and reached the exact
    opposite conclusion of the Majority Opinion’s holding that “the exercise of federal
    jurisdiction over this state-law malpractice claim would disturb the balance between
    federal and state judicial responsibilities.” Majority Op. at 13. The Court of Appeals
    for the Federal Circuit held that the exercise of state jurisdiction over a state legal
    malpractice claim like Minton’s requiring a “trial within a trial” of the underlying
    patent infringement suit would disturb the congressionally mandated balance
    between federal and state judicial responsibilities. See 
    AMT, 504 F.3d at 1272
    ;
    
    Immunocept, 504 F.3d at 1285
    -86.
    Finally, the Majority Opinion holds that Section 1338 jurisdiction is not
    triggered because application of the on sale bar rule and the experimental use
    exception in Minton’s legal malpractice claim are “fact-bound and situation-specific”
    issues. Majority Op. at 15 (citing 
    Empire, 547 U.S. at 699
    –701, 126 S. Ct. at 2136).
    The “fact-bound and situation-specific” aspect of the Majority Opinion’s analysis is
    clearly incorrect. It puts the cart before the horse; a court cannot look past the
    jurisdictional issue, examine the merits of state court summary judgment evidence,
    decide that issues are fact-bound and situation-specific, and then use its decision
    18
    on the merits to retroactively defeat Section 1338 jurisdiction. Instead, as outlined
    above, Section 1338 jurisdiction is to be determined based on the well-pleaded
    complaint doctrine and a federalism analysis, not on summary judgment evidence
    or non-evidence or the fact that the case was subsequently disposed of by
    summary judgment. See 
    Lockwood, 93 Cal. Rptr. 3d at 228
    –29 (explaining that
    trial court should have dismissed for lack of subject matter jurisdiction, not granted
    summary judgment, and rejecting defense’s argument that these two outcomes are
    equivalent).   For these reasons, I cannot agree with the Majority Opinion’s
    federalism analysis.
    19
    V. CONCLUSION
    I would hold that the federal courts possess Section 1338 jurisdiction over
    Minton’s state legal malpractice suit that requires proof of every element of his
    underlying patent infringement suit. I would grant Minton’s motion to dismiss,
    vacate the trial court’s order granting summary judgment for Appellees, and remand
    the case to the trial court for disposition in accordance with this opinion.
    SUE WALKER
    JUSTICE
    DELIVERED: October 8, 2009
    20
    

Document Info

Docket Number: 02-06-00443-CV

Filed Date: 10/8/2009

Precedential Status: Precedential

Modified Date: 2/1/2016

Authorities (52)

robert-d-custer-as-a-participant-of-and-trustee-for-the-sheet-metal , 89 F.3d 1156 ( 1996 )

Singh v. Duane Morris LLP , 538 F.3d 334 ( 2008 )

IMMUNOCEPT, LLC v. Fulbright & Jaworski, LLP , 504 F.3d 1281 ( 2007 )

Steven G. Lough v. Brunswick Corporation, D/B/A Mercury ... , 86 F.3d 1113 ( 1996 )

Scherbatskoy v. Halliburton Company , 125 F.3d 288 ( 1997 )

elizabeth-a-marsh-of-the-estate-of-william-e-marsh-jr-and-elizabeth , 744 F.2d 1077 ( 1984 )

Cargill, Inc. v. Canbra Foods, Ltd. , 476 F.3d 1359 ( 2007 )

Scaltech Inc. v. Retec/tetra, L.L.C. , 178 F.3d 1378 ( 1999 )

Western Marine Electronics, Inc., Appellant/cross-Appellee ... , 764 F.2d 840 ( 1985 )

Nathaniel H. Kolmes and Harold F. Plemmons v. World Fibers ... , 107 F.3d 1534 ( 1997 )

Robert M. Sinskey v. Pharmacia Ophthalmics, Inc. , 982 F.2d 494 ( 1992 )

Petrolite Corporation v. Baker Hughes Incorporated and ... , 96 F.3d 1423 ( 1996 )

lacks-industries-inc-v-mckechnie-vehicle-components-usa-inc-doing , 322 F.3d 1335 ( 2003 )

hunter-douglas-inc-and-hunter-douglas-fabrication-company-v-harmonic , 153 F.3d 1318 ( 1998 )

In Re James T. Hamilton , 882 F.2d 1576 ( 1989 )

Paragon Podiatry Laboratory, Inc. v. Klm Laboratories, Inc. , 984 F.2d 1182 ( 1993 )

Additive Controls & Measurement Systems, Inc. v. Flowdata, ... , 986 F.2d 476 ( 1993 )

Electromotive Division of General Motors Corp. v. ... , 417 F.3d 1203 ( 2005 )

The D.L. Auld Company v. Chroma Graphics Corp. , 714 F.2d 1144 ( 1983 )

Air Measurement Technologies, Inc. v. Akin Gump Strauss ... , 504 F.3d 1262 ( 2007 )

View All Authorities »